Glialogix is developing GLX1112 as a breakthrough therapy for progressive multiple sclerosis, a devastating disease with no effective treatments. GLX1112 is an improved formulation of an FDA-approved drug that has previously shown a large efficacy signal in progressive MS patients. Their therapeutic approach is neuroprotective and designed to slow the accumulation of disability by reducing chronic damage to neurons and oligodendrocytes.